News & Resources

How Pharma Can Digitize Interactions With HCPs

Today, there is a notable number of physicians in both the US and in Europe who use e-health technologies.

While the adoption of electronic medical records is higher among European physicians, over 80% of HCPs in the US now use a smartphone for work, and 50% report using a tablet, according to an Epocrates study. This signals a great need for pharma companies to take advantage of digital technology trends in their marketing strategies. With the adoption of mobile devices and the ability to access the internet anywhere, anytime, the rules of engagement have changed, along with traditional interactions between HCPs and pharma companies. This post will discuss why online engagement is appropriate and the ways pharma can better digitize interactions with HCPs.

How do HCPs use digital channels in their practice?
More HCPs turn to digital channels today in order to access professional information and educate themselves on new medical approaches, not to mention keep up with tech-savvy patients. Additionally, good communications strategies have taught us the importance of providing HCPs with the content they want via the channels they use in order to strengthen engagement practices. Knowing that HCPs already go online to find information and education on specific healthcare topics, it will be to the pharma industry’s benefit to provide access to high-quality content while facilitating valuable digital interactions.

That said, for pharma companies to more effectively interact with HCPs on a digital level, they need to further understand HCPs’ so-called digital modes of interaction. Of course, individual HCPs use different digital channels, whether it be Web sites, email, closed-network messaging, social media, or Web-based forums. Because of this, many pharma companies are interested in the digital preferences of HCPs as a way to understand how to better engage them.

How can pharma improve HCP engagement using digital channels?
One fact to consider is that the role of the sales rep is no longer the center of the pharmaceutical space. It has been found that HCPs generally want to explore information on their own, which creates a shift away from traditional engagement strategies. Rather than focusing on in-person events for disseminating knowledge, pharma companies now need to consider how to provide HCPs digital constructs to interact with the information. Digitizing a platform for HCP engagement creates a personalized digital connection with your HCPs and offers them a convenient, sustainable, and flexible mode of interaction.

With a growing preference for digital modes of interaction, pharma companies need to re-examine and refine the way in which they digitize interactions with HCPs. Digital engagement activities should focus on the HCP experience. This means pharma companies should empower HCPs to determine how they interact within a digital framework, track their digital footprint, and, on the basis of HCP preferences, digitize channels for maximizing HCP interactions.

A pharma company should consider a platform that is versatile in its capabilities: it should support live audio/video conferencing, digital content management, intuitive interaction, and be optimized across multiple channels, including mobile, Web, and social. To effectively digitize interactions with HCPs, the platform should ideally be fit with compelling, relevant, and highly targeted content in order to invite lasting HCP engagement.

How can pharma use mobile applications to invite HCP interaction?
Mobile apps are being created to target not only patients but HCPs as well, providing a new course for the pharma industry to strategically approach HCPs. Understanding HCPs’ preference for apps, one bold suggestion to pharma companies is to develop their own mobile app targeting HCPs and simplifying access to tailored content and services. A great approach is to partner with a specialized medical communications agency to help develop an app that allows HCPs to interact with valuable clinical data or access education modules on new medical advances and treatments. It should integrate other modes of digital engagement as well, like virtual Web conferences, closed-network discussion forums and messaging, content sharing, and more.

How can pharma benefit from digitizing interactions with HCPs?
Using a digital platform to connect with HCPs, pharma marketers can track and analyze interactions. For example, an HCP’s response to a new scientific advancement or notes from a virtual discussion introducing a new drug can be recorded and studied. By developing digital profiles and studying the history of an HCP’s digital interactions, pharma marketers and sales reps in the future will be much more proactive in understanding their HCPs’ needs. When you digitize interactions with HCPs, you will ultimately be provided with valuable analytic insight that can help steer the course of a new marketing campaign, aid in the development of a new treatment, or even contribute to course material for HCPs interested in continued education content.

Therapeutic Area

Archives

Matthew Gordon

VP, Real-World Evidence
Matthew has more than 25 years of experience in real-world evidence and observational, non-interventional research. He has led studies across the full life cycle—from startup through publication—supporting objectives that range from understanding a disease’s natural history to fulfilling global safety surveillance requirements. Matthew brings deep expertise in orphan disease programs, having overseen more than 25 long-term, global initiatives, as well as in disease and product registries, prospective pharmacoeconomic studies, and systematic literature reviews. Matthew leads the RWE Registries team, responsible for building the business and team. Prior to joining Aptitude Health, he held senior leadership roles at Parexel, Worldwide Clinical Trials, inVentiv Health Clinical, Quintiles Outcome, and ICON Clinical Research. Matthew holds a BA in sociology from Boston University, is a long-standing member of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and is a frequent speaker at ISPOR, the Center for Business Intelligence, and related industry conferences.

Gerald Stanvitch, PhD

VP, Scientific Content

Cate Browning, PhD

VP, Global Medical Affairs

Erin Zingales Rau

VP, Account Services

Kelly Kocor

VP, People & Culture
Kelly leads both the human resources and talent acquisition teams, ensuring that Aptitude Health attracts, retains, and develops top personnel to drive our continued success. With over 17 years of experience transforming global HR initiatives, Kelly is an expert in harmonizing HR policies and fostering a culture of engagement and partnership. She is committed to partnering with all areas of the business to ensure full regulatory compliance and delivering value-added services to our organization and its people. Kelly is passionate about developing and implementing HR strategies that help support our employees’ professional and personal growth. She is dedicated to fostering a culture that encourages innovation, collaboration, and inclusivity, helping Aptitude Health continue to be a great place to work.

Bart Zygmond

VP, Finance
Bart brings a wealth of experience to the organization, having worked in the life sciences, pharmaceuticals, manufacturing, and service industries. With his expertise in financial reporting, US GAAP, SOX, cash flow modeling, and financial analysis, he plays a crucial role in the company’s financial management and strategy. Prior to joining Aptitude Health as VP, Finance, Bart held several controller positions: at Q2 Solutions, he oversaw the global finance team and financial operations, ensuring the accurate and timely financial reporting of the company. He also held controller positions at Domtar Inc and Veristat.

Eugene Vissers, MD

Senior VP, Global Scientific Content
Eugene is a seasoned medical doctor with over 20 years of international experience in pharma, consultancy, and agency environments. Eugene leads the US team of dedicated experts responsible for developing high-quality medical content. Prior to joining Aptitude Health, Eugene served as medical director at Ipsen and AstraZeneca. With both his medical degree and an MBA, Eugene brings a unique perspective to his role. His clinical background, combined with his business acumen, allows him to develop innovative strategies that drive results. Under Eugene’s leadership, the medical content team delivers scientific information of the highest quality, providing valuable insights to our clients around the world.

Adrian Barfield

VP, US Business Development

Kelley Hernandez

Executive VP, US Business Development
Kelley has over 18 years of experience in the oncology space. Kelley joined Aptitude Health after working with Cardinal Health, where she was part of the Healthcare and Analytics Division, and finished her tenure there with VitalSource™ (GPO division). As the leader of the strategic business development team for the US, Kelley brings a wealth of expertise to the organization. Her experience in the healthcare industry, combined with her ability to identify and capitalize on new business opportunities, is invaluable in driving the company’s growth and success. Kelley’s dedication to building strong relationships with life science partners is a testament to her commitment to delivering exceptional value to the healthcare industry.

Adam Sinensky, MBA

Chief Technology Officer

Adam has over 20 years of experience in the healthcare industry and an MBA in healthcare management. After 10 years as a strategy consultant to life science companies, Adam has spent the last decade as a product and strategy leader focused on bringing technology products to market across the payor, provider, and life sciences segments. By combining his business acumen and experience working directly with software developers, engineers, and data scientists, Adam has successfully led numerous product launches and enhancements from ideation to development and go-to-market initiatives. His product and change management expertise has led organizational shifts from services to technology at companies such as Change Healthcare and Datavant/Ciox. At Aptitude Health, Adam is responsible for growing our portfolio of product offerings by leveraging real-world data and artificial intelligence with our existing solutions and industry-leading Axess Network of healthcare providers. He also oversees our IT and cybersecurity teams.

Stefanie Daniels

Chief Commercial Officer

Stefanie is a seasoned healthcare executive with over 20 years of experience in oncology. She brings a wealth of knowledge and expertise to the organization. Stefanie joined Aptitude Health after spending over a decade as a senior director at Physicians’ Education Resource, an oncology CME vendor. During her tenure, she led and managed teams responsible for grant development/acquisition, program creation/execution, and faculty management. Stefanie’s deep understanding of the oncology industry and her ability to lead teams through complex projects make her a vital part of the organization’s success. Her dedication to providing high-quality solutions to our life science partners is a testament to her commitment to improving cancer patient care.

Jason Cash

Chief Financial Officer

Jason is an accomplished finance professional with over 20 years of experience in the pharmaceutical services industry. Throughout his career, he has demonstrated a keen ability to navigate high-growth organizations, delivering exceptional results. Before joining Aptitude Health, Jason served as the CFO of Veristat International, a global contract research organization. In this role, he led the financial strategy and played a pivotal role in driving the company’s growth and success. Jason’s wealth of experience and expertise in financial management make him an essential member of the leadership team. His strategic thinking and ability to drive results are highly respected within the industry.

Jez Moulding

Chief Executive Officer
Jez is a seasoned leader with over 20 years of experience in general management and regional president roles. He has a proven track record of success in the healthcare industry, having worked in the US, Japan, Australia, Korea, South Africa, France, and the UK for Sanofi, where he supported the launch of 10 new drugs across various therapeutic areas. As chief commercial officer at UDG Healthcare and EVP at Ashfield, Jez demonstrated his expertise in developing and implementing successful business strategies. He joined Aptitude Health from Pharmaspectra, an IQVIA business, where he served as CEO since 2018. Jez’s extensive experience in the pharmaceutical industry and his leadership skills make him an invaluable asset to the organization.
Aptitude Health
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.